ArticleVirology journal2025
HPV genotype distribution and cervical lesion severity in HPV-positive women: a study from the Guizhou Province cervical cancer screening program.
Article in Virology journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- From HPV genotypes to cervical lesion burden: public health-relevant heterogeneity across 1.29 million screening records in Guangdong, China.Frontiers in public health · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
objectiveTo analyze the infection status and subtype distribution of high-risk human papillomavirus (hrHPV) and their relationship with cervical lesions among women undergoing cervical cancer screening in Guizhou Province, thereby informing HPV vaccine selection and optimizing cervical cancer screening strategies.
methodsData were sourced from the 2024 Guizhou Province free cervical cancer screening program for women. The prevalence of hrHPV-positive samples was analyzed, and age-specific associations between HPV genotypes and severe lesions were explored. Furthermore, the co-infection propensity for any two HPV genotypes was assessed by calculating the infection rate ratio.
resultsThe overall hrHPV infection rate in the Guizhou region of China was 10.09%. Among hrHPV-positive individuals, the detection rate of cervical lesions was 11.49%. In hrHPV-positive women with cervical lesions, the most common genotypes were HPV16, 52, and 58. HPV16 was predominant across the entire spectrum of cervical lesions, and its prevalence increased significantly with the severity of cervical lesions, from 21.7% in LSIL to 39.4% in HSIL, and to 56.7% in cervical cancer (p < 0.001). However, the primary HPV types leading to cervical cancer were HPV16, 18, and 33. The infection pattern was predominantly single genotype (71.8%), with multiple genotypes accounting for only 28.2%. Among multiple infections, dual infection was the most common. The most frequent mixed genotype combinations were HPV16 + 52, 52 + 58, and 16 + 58. Significant co-infection preferences were observed for HPV16 with 33, HPV16 with 58, and HPV18 with 59. Analysis of the association between HPV genotype risk grouping and age across different cervical lesion grades showed that in the LSIL group, women aged 55-65 had a significantly 24% higher risk of HPV16 infection compared to those aged 35-45 (P = 0.023), while the risk of 'Other hrHPV' infection was significantly reduced by 8% (P = 0.019). In the HSIL group, the 45-55 age group had a significantly 11% lower risk of 'Other hrHPV' infection compared to the 35-45 age group.
conclusionHPV16 predominates across the entire cervical lesion spectrum, with its prevalence significantly increasing with lesion severity. Furthermore, the nonavalent HPV vaccine covers all prevalent oncogenic hrHPV genotypes in this region (except for HPV56). These findings provide crucial epidemiological evidence for optimizing HPV vaccination strategies and cervical cancer screening programs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.